What is Infinity Pharmaceuticals, Inc. (INFIQ) stock price today?

Infinity Pharmaceuticals, Inc. (INFIQ) is currently trading at $0.00.

What is INFIQ P/E ratio?

Infinity Pharmaceuticals, Inc.'s P/E ratio is 0.00. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is INFIQ return on equity (ROE)?

Infinity Pharmaceuticals, Inc.'s return on equity (ROE) is 231.58%, indicating how efficiently the company generates profit from shareholders' equity. This is considered high quality.

What is Infinity Pharmaceuticals, Inc.'s market cap?

Infinity Pharmaceuticals, Inc. has a market capitalization of $9076.

OTC · Biotechnology

Infinity Pharmaceuticals, Inc. (INFIQ) Stock

$0.00 OTC: INFIQ Healthcare

Valuation

Metric	Value
Price	$0.00
Market Cap	$9076
P/E Ratio	0.00
P/B Ratio	0.00
P/S Ratio	0.00
EPS (TTM)	$-0.50
52-Week High	$0.00
52-Week Low	$0.00
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	231.58%
ROA	-60.70%
ROCE	-157.22%
Gross Margin	-1466.67%
Operating Margin	-1500.00%
Net Margin	-1466.67%
Debt/Equity	-2.53
Current Ratio	1.65

Annual Financials (USD)

Metric	2019	2020	2021	2022
Revenue	$3.0M	$2.0M	$2.0M	$3.0M
Operating Profit	$-46.0M	$-38.0M	$-45.0M	$-45.0M
Net Profit	$-47.0M	$-40.0M	$-45.0M	$-44.0M
EPS	$-0.83	$-0.68	$-0.53	$-0.50
Op Margin	-1497.7%	-2239.5%	-2426.4%	-1729.4%

Balance Sheet (USD)

Metric	2019	2020	2021	2022
Total Assets	$49.0M	$39.0M	$85.0M	$42.0M
Total Liabilities	$41.0M	$62.0M	$63.0M	$61.0M
Cash	$22.0M	$29.0M	$81.0M	$38.0M
Borrowings	$32.0M	$24.0M	$51.0M	$48.0M

Cash Flow (USD)

Metric	2019	2020	2021	2022
Operating Cash Flow	$-42.0M	$-36.0M	$-41.0M	$-42.0M
Investing Cash Flow	$-15.0M	$15.0M	$5.0M	$0
Financing Cash Flow	$28.0M	$0	$0	$0
Net Cash Flow	$-26.0M	$6.0M	$52.0M	$-42.0M
Free Cash Flow	$-44.0M	$-36.0M	$-41.0M	$-42.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	0.00
EV / EBITDA	-0.22
FCF Yield	-467695.02%
Quick Ratio	2.96
Interest Coverage	-249.13
Return 1Y	900.00%
Return 3Y	-99.92%
Return 5Y	-100.00%

Ownership

Insiders Held0.00%

Institutions Held0.00%

Institutions Float Held0.00%

Institutional Holder	Shares	Report Date
Motiv8 Investments LLC	200	2025-12-31

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
AFIBAcutus Medical, Inc.	$0.00	—	0.00	$2991	0.00%
ARDSAridis Pharmaceuticals, Inc.	$0.00	—	0.00	$4457	0.00%
BTAXBiostax Corp.	$0.00	—	0.00	$7871	0.00%
EVLOEvelo Biosciences, Inc.	$0.00	—	0.00	$1898	0.00%
HSTCHST Global, Inc.	$0.70	+0.00%	-250.00	$29.94M	0.00%

About Infinity Pharmaceuticals, Inc.

Infinity Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel medicines for people with cancer. The company's product candidate, including eganelisib (IPI-549), an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors. Infinity Pharmaceuticals, Inc. has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Cambridge, Massachusetts. On September 29, 2023, Infinity Pharmaceuticals, Inc. along with its affiliate, a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. The plan was later approved as Chapter 11 liquidation on March 7, 2024.

Infinity Pharmaceuticals, Inc. (INFIQ) stock trades at $0.00 with a market capitalization of $9076. The stock is valued at a price-to-earnings (P/E) ratio of 0.00, price-to-book of 0.00, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.00 and $0.00, and currently trades —% below its 52-week high.

On profitability, Infinity Pharmaceuticals, Inc. generates a return on equity (ROE) of 231.58% — well above the market average, a sign of a high-quality business, return on capital employed of -157.22%, an operating margin of -1500.00%, a net profit margin of -1466.67%.

Official website: www.infi.com

Related Healthcare Stocks

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks All stock screens

Run Stock Screener Investing Guides